Jonathan Halford to Anticonvulsants
This is a "connection" page, showing publications Jonathan Halford has written about Anticonvulsants.
Connection Strength
2.443
-
A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies. Epilepsy Res. 2021 08; 174:106646.
Score: 0.640
-
Correlation of seizure frequency and medication down-titration rate during video-EEG monitoring. Epilepsy Behav. 2016 11; 64(Pt A):51-56.
Score: 0.467
-
A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures. Epilepsia. 2011 Apr; 52(4):816-25.
Score: 0.316
-
Long-term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program. Epilepsia. 2022 01; 63(1):139-149.
Score: 0.167
-
Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy: A Phase 2 Study. Neurology. 2021 11 02; 97(18):e1757-e1767.
Score: 0.164
-
Seizure freedom as an outcome in epilepsy treatment clinical trials. Acta Neurol Scand. 2020 Aug; 142(2):91-107.
Score: 0.150
-
Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020 06; 61(6):1099-1108.
Score: 0.150
-
Randomized trial of lacosamide versus fosphenytoin for nonconvulsive seizures. Ann Neurol. 2018 06; 83(6):1174-1185.
Score: 0.131
-
Intravenous carbamazepine as short-term replacement therapy for oral carbamazepine in adults with epilepsy: Pooled tolerability results from two open-label trials. Epilepsia. 2015 Jun; 56(6):906-14.
Score: 0.106
-
Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials. Epilepsia. 2010 Mar; 51(3):333-43.
Score: 0.072
-
Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial. Epilepsia. 2021 10; 62(10):2505-2517.
Score: 0.041
-
Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial. Epilepsia. 2021 09; 62(9):2228-2239.
Score: 0.041